NASDAQ:NVTR - Nuvectra Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $17.59 -0.40 (-2.22 %) (As of 12/11/2018 12:31 PM ET)Previous Close$17.99Today's Range$17.59 - $18.3552-Week Range$7.60 - $25.17Volume1,924 shsAverage Volume146,557 shsMarket Capitalization$315.55 millionP/E Ratio-4.30Dividend YieldN/ABeta-0.37 ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs. It also designs, manufactures, and sells neural interface technologies, including microelectrode arrays, custom designed probes, and electrode instrumentation and accessories; and develops Virtis, a sacral neuromodulation system for the treatment of chronic urinary retention and overactive bladder. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas. Receive NVTR News and Ratings via Email Sign-up to receive the latest news and ratings for NVTR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVTR Previous SymbolNASDAQ:NVTRV CUSIPN/A Webwww.nuvectramed.com Phone214-474-3103 Debt Debt-to-Equity Ratio0.42 Current Ratio7.63 Quick Ratio7.35 Price-To-Earnings Trailing P/E Ratio-4.30 Forward P/E Ratio-5.27 P/E GrowthN/A Sales & Book Value Annual Sales$31.84 million Price / Sales9.73 Cash FlowN/A Price / Cash FlowN/A Book Value$4.47 per share Price / Book3.94 Profitability EPS (Most Recent Fiscal Year)($4.22) Net Income$-44,600,000.00 Net Margins-87.94% Return on Equity-65.86% Return on Assets-36.96% Miscellaneous Employees195 Outstanding Shares17,610,000Market Cap$315.55 million OptionableOptionable Nuvectra (NASDAQ:NVTR) Frequently Asked Questions What is Nuvectra's stock symbol? Nuvectra trades on the NASDAQ under the ticker symbol "NVTR." How were Nuvectra's earnings last quarter? Nuvectra Corp (NASDAQ:NVTR) posted its quarterly earnings results on Monday, October, 29th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.86) by $0.01. The company had revenue of $14.22 million for the quarter, compared to the consensus estimate of $12.38 million. Nuvectra had a negative net margin of 87.94% and a negative return on equity of 65.86%. View Nuvectra's Earnings History. When is Nuvectra's next earnings date? Nuvectra is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Nuvectra. What price target have analysts set for NVTR? 4 equities research analysts have issued 12-month target prices for Nuvectra's stock. Their predictions range from $21.00 to $27.00. On average, they anticipate Nuvectra's share price to reach $24.00 in the next year. This suggests a possible upside of 36.4% from the stock's current price. View Analyst Price Targets for Nuvectra. What is the consensus analysts' recommendation for Nuvectra? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra. Has Nuvectra been receiving favorable news coverage? Headlines about NVTR stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nuvectra earned a coverage optimism score of 1.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. Who are some of Nuvectra's key competitors? Some companies that are related to Nuvectra include Nevro (NVRO), AtriCure (ATRC), K2M Group (KTWO), Orthofix Medical (OFIX), Cryolife (CRY), Cardiovascular Systems (CSII), Tactile Systems Technology (TCMD), Intersect ENT (XENT), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), Cerus (CERS), LeMaitre Vascular (LMAT), Antares Pharma (ATRS) and SI-Bone (SIBN). Who are Nuvectra's key executives? Nuvectra's management team includes the folowing people: Mr. Scott F. Drees, CEO & Director (Age 60)Mr. Joseph Paul Hanchin, Pres (Age 56)Mr. Walter Z. Berger, COO, CFO & Exec. VP (Age 62)Ms. Jennifer J. Kosharek, VP, Controller & Principal Accounting Officer (Age 37)Mr. Benjamin Tranchina, Chief Technology Officer Who are Nuvectra's major shareholders? Nuvectra's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.43%), Dimensional Fund Advisors LP (4.23%), Vanguard Group Inc. (3.85%), Peregrine Capital Management LLC (4.19%), Russell Investments Group Ltd. (3.79%) and Rockefeller Capital Management L.P. (2.45%). Company insiders that own Nuvectra stock include Joseph A Miller, Joseph Paul Hanchin, Scott F Drees, Thomas Edward Zelibor and Thomas Kelley Hickman. View Institutional Ownership Trends for Nuvectra. Which institutional investors are selling Nuvectra stock? NVTR stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Hodges Capital Management Inc., JPMorgan Chase & Co., Perceptive Advisors LLC, Laurel Wealth Advisors Inc., Raffles Associates LP and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Nuvectra. Which institutional investors are buying Nuvectra stock? NVTR stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Point72 Asset Management L.P., Russell Investments Group Ltd., AWM Investment Company Inc., Falcon Point Capital LLC, Northpointe Capital LLC, BlackRock Inc. and Monashee Investment Management LLC. Company insiders that have bought Nuvectra stock in the last two years include Joseph A Miller, Scott F Drees and Thomas Edward Zelibor. View Insider Buying and Selling for Nuvectra. How do I buy shares of Nuvectra? Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Nuvectra's stock price today? One share of NVTR stock can currently be purchased for approximately $17.59. How big of a company is Nuvectra? Nuvectra has a market capitalization of $315.55 million and generates $31.84 million in revenue each year. The company earns $-44,600,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis. Nuvectra employs 195 workers across the globe. What is Nuvectra's official website? The official website for Nuvectra is http://www.nuvectramed.com. How can I contact Nuvectra? Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected] MarketBeat Community Rating for Nuvectra (NASDAQ NVTR)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 165 (Vote Outperform)Underperform Votes: 149 (Vote Underperform)Total Votes: 314MarketBeat's community ratings are surveys of what our community members think about Nuvectra and other stocks. Vote "Outperform" if you believe NVTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/11/2018 by MarketBeat.com StaffFeatured Article: Why is insider trading harmful?